Spinocerebellar AtaxiaSymptoms, Doctors, Treatments, Advances & More
Spinocerebellar Ataxia Overview
Learn About Spinocerebellar Ataxia
View Main Condition: Movement Disorders
East Ann Arbor Health & Geriatrics Center
Henry Paulson is a Neurologist practicing medicine in Ann Arbor, Michigan. Dr. Paulson is rated as an Elite provider by MediFind in the treatment of Spinocerebellar Ataxia. He is also highly rated in 41 other conditions, according to our data. His clinical expertise encompasses Olivopontocerebellar Atrophy, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia, and Drug Induced Dyskinesia. Dr. Paulson is board certified in Neurology. Dr. Paulson is currently accepting new patients.
UChicago Medicine Duchossois Center For Advanced Medicine - Hyde Park
Christopher Gomez is a Neurologist practicing medicine in Chicago, Illinois. Dr. Gomez is rated as an Elite provider by MediFind in the treatment of Spinocerebellar Ataxia. He is also highly rated in 40 other conditions, according to our data. His clinical expertise encompasses Spinocerebellar Ataxia, Olivopontocerebellar Atrophy, Acute Cerebellar Ataxia, Gastrostomy, and Stent Placement. Dr. Gomez is board certified in Neurology and Practicing Since1990. Dr. Gomez is currently accepting new patients.
Puneet Opal is a Neurologist practicing medicine in Chicago, Illinois. Dr. Opal is rated as an Elite provider by MediFind in the treatment of Spinocerebellar Ataxia. He is also highly rated in 18 other conditions, according to our data. His clinical expertise encompasses Spinocerebellar Ataxia Type 1, Olivopontocerebellar Atrophy, Giant Axonal Neuropathy, and Spinocerebellar Ataxia. Dr. Opal is board certified in American Board Of Psychiatry And Neurology - Neurology (Certified). Dr. Opal is currently accepting new patients.
Summary: A pivotal, randomized, double-blind, placebo-controlled, multi-center therapeutic study for patients age 4 and older with a confirmed diagnosis of CACNA1A. The objective of this study is to evaluate the safety, tolerability and efficacy of N-acetyl-L-leucine (IB1001) compared to standard of care.
Summary: An open label study designed to evaluate the safety, PK, PD, and clinical effects of long-term daily administration of CTI-1601 enrolling adolescent and adult patients with FRDA who have participated in a prior clinical study of CTI-1601 as well as children (age 2 years and older), adolescents and adults with FRDA who have not participated in a prior clinical study of CTI-1601.

